You have read all your free articles, to continue reading subscribe to read the rest of this content.
The next phase in the company's strategy towards 2023 is expected to affect around 1,000 positions in the global organization over the next two years. In 2020, LEO Pharma unveiled its strategy towards 2030. The first phase of this process – including the introduction of a new capital Already a subscriber Login You have read…
Swedish Orphan Biovitrum has announced that it intends to discontinue discovery/early research and partner R&D programmes outside its core focus areas. The new focus of the R&D organisation is expected to lead to annual savings of SEK 200–300 M on a full-year basis in 2020, which will iAlready a subscriber…
Nexstim announces that it is raising new equity financing of the gross amount EUR 1.75 million via a directed issue of new shares to a London-based fund managed by City Financial Investment Company Limited. The Company’s Board of Directors resolved to issue up to 7,000,000 new shares at a subscAlready…
Menarini Asia-Pacific, a member of the Menarini Group, has been granted the exclusive rights to market and sell Moberg Pharma’s Kerasal Nail on the Chinese market. Kerasal Nail is a non-prescription product for the treatment of discoloured and deformed nails resulting from fungal infection or Already a subscriber Login You have…
